BioNTech SE - American Depositary Shares (BNTX)
100.00
+0.00 (0.00%)
NASDAQ · Last Trade: Sep 2nd, 9:08 AM EDT
Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest.
Via Benzinga · September 1, 2025
Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades.
Via Benzinga · August 31, 2025
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing.
Via Benzinga · August 27, 2025
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Populationstocktwits.com
Via Stocktwits · August 27, 2025
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Pushstocktwits.com
Via Stocktwits · August 4, 2025
Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday.
Via Investor's Business Daily · August 27, 2025
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic.
Via Benzinga · August 25, 2025
This big pharma company's juicy dividend is looking even more attractive.
Via The Motley Fool · August 13, 2025
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy.
Via Benzinga · August 12, 2025
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.
Via Benzinga · August 11, 2025
Via Benzinga · August 5, 2025
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance.
Via Benzinga · August 4, 2025
BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances.
Via Chartmill · August 4, 2025
In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,
Via MarketMinute · August 4, 2025
Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce.
Via Benzinga · August 1, 2025
Bristol Myers beat Q2 sales expectations but cut its 2025 EPS forecast as strategic charges and legacy product declines weighed on earnings.
Via Benzinga · July 31, 2025
The big drugmaker should be even bigger over the next five years despite facing a patent cliff.
Via The Motley Fool · July 31, 2025
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken and failing its intended purpose.
Via Benzinga · July 28, 2025
AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.
Via Benzinga · July 10, 2025
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute.
Via Benzinga · July 10, 2025